Wednesday, December 3, 2025

Cognetivity Neurosciences Sees Former UK Health Minister Appointed To Advisory Board

Cognetivity Neurosciences (CSE: CGN) this morning announced that it has added a former UK Health Minister to its advisory board. The appointment will see Lord O’Shaughnessy to the firms advisory board, effective immediately.

A member of the UK House of Lords, which is an upper house of the parliament within the United Kingdom, O’Shaughnessy comes highly experienced in the field of healthcare. Previously, he served as parliamentary under-secretary of state at the Department of Health, while also serving as the lead for the Medicines and Healthcare products Regulatory Agency, or MHRA.

Outside of his involvement in healthcare, James O’Shaughnessy has also served as a director of polcy to Prime Minister David Cameron and is currently a visiting professor for the Institute of Global Health Innovation at Imperial College London. Within healthcare, he currently serves as an advisor or director at a number of firms including Health Data Research UK, Healthy.io, Push Doctor, Bain & Company, and a number of healthcare related ventures.

“There’s no doubt that the future of healthcare looks increasingly digital – there are enormous improvements in patient outcomes to be made through the use of innovative technology. I greatly look forward to working with the team to ensure Cognetivity’s technology is able to improve the lives of as many people as possible.”

Lord O’Shaughnessy

Cognetivity Neurosciences last traded at $0.58 on the CSE.


FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Why Copper Is Heading To $30 And Silver To $200 | Craig Parry

Mako Mining Q3 Earnings: The Transitional Quarter

B2Gold Q3 Earnings: Goose Troubles Cloud The Narrative

Recommended

Goliath Resources Extends Bonanza Zone To 1.25 Kilometres Length In Latest Assays

PTX Metals Commences 5,000 Metre Drill Program At W2 Property

Related News

Cognetivity Neurosciences Sees Granting Of FDA Clearance For Cognitive Assessment Tool

Cognetivity Neurosciences (CSE: CGN) has reached a major achievement. The company has been granted FDA...

Wednesday, October 20, 2021, 09:22:23 AM

Cognetivity Neurosciences Signs Commercial Deal With Dubai Health Authority

Cognetivity Neurosciences (CSE: CGN) continues to expand the deployment of its Integrated Cognitive Assessment, or...

Wednesday, March 2, 2022, 09:30:37 AM

Cognetivity’s Brain Health Monitoring App – The Daily Dive

On this Daily Dive episode, Cassandra talks to Dr. Sina Habibi, CEO of Cognetivity Neurosciences...

Friday, November 19, 2021, 03:28:00 PM

Cognetivity Neurosciences Selected For Accelerator Program To Fast Track US Commercialization

Cognetivity Neurosciences (CSE: CGN) has been selected as one of just seven members of the...

Wednesday, December 23, 2020, 09:08:31 AM

Cognetivity Sees Its Cognitive Tool Used In Clinical Study For OCD

While it may have been initially developed for the early detection of Alzheimer’s disease or...

Tuesday, September 13, 2022, 08:38:28 AM